Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_assertion type Assertion NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_head.
- NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_assertion description "[Importantly, a related MCT1/2 inhibitor (AZD3965) is currently in phase I clinical trials in patients with advanced cancers: http://clinicaltrials.gov/show/NCT01791595.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_provenance.
- NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_assertion evidence source_evidence_literature NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_provenance.
- NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_assertion SIO_000772 25415228 NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_provenance.
- NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_assertion wasDerivedFrom befree-2016 NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_provenance.
- NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_assertion wasGeneratedBy ECO_0000203 NP1239102.RA7-JSI-i_mADfPMEK93L3oOMc2_BUIvw8_02-tDVgGi8130_provenance.